SEYMOUR H FEIN, M.D.
Osteopathic Medicine at Canoe Hill Rd, New Canaan, CT
License number
Connecticut 41399
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
476 Canoe Hill Rd, New Canaan, CT 06840
Phone
(203) 972-8823
Professional information
Dr. Seymour H Fein, New Canaan CT - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
476 Canoe Hill Rd, New Canaan 06840
(203) 972-8823 (Phone)
(203) 972-8823 (Phone)
Certifications:
Internal Medicine, 1977, Medical Oncology, 1979
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York Medical College
Graduated: 1974
Dartmouth-Hitchcock Med Ctr
Beth Israel Deaconess Medical Center
New York Medical College
Graduated: 1974
Dartmouth-Hitchcock Med Ctr
Beth Israel Deaconess Medical Center
Methods And Devices For Desmopressin Drug Delivery
US Patent:
2014005, Feb 27, 2014
Filed:
Feb 15, 2013
Appl. No.:
13/768510
Inventors:
Seymour H. Fein - New Canaan CT, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61M 5/168, A61N 1/30, A61M 37/00, A61M 35/00
US Classification:
604 20, 604289, 604 22, 604257, 604173, 604246, 604285
Abstract:
Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.
Methods For Preventing Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
US Patent:
7947285, May 24, 2011
Filed:
May 16, 2005
Appl. No.:
11/130428
Inventors:
Seymour H. Fein - New Canaan CT, US
Edward D. Purich - Silver Spring MD, US
Paul S. Jowell - Chapel Hill NC, US
John Baillie - Durham NC, US
Edward D. Purich - Silver Spring MD, US
Paul S. Jowell - Chapel Hill NC, US
John Baillie - Durham NC, US
International Classification:
A61K 36/00, A61K 36/16
US Classification:
4241981, 514 128, 530350
Abstract:
The invention relates generally to methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.
Pharmaceutical Compositions Including Low Dosages Of Desmopressin
US Patent:
2012032, Dec 20, 2012
Filed:
Aug 30, 2012
Appl. No.:
13/599768
Inventors:
Seymour H. Fein - New Canaan CT, US
International Classification:
A61K 38/11, A61P 7/08, A61P 13/00
US Classification:
514 109
Abstract:
The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Pharmaceutical Compositions Including Low Dosages Of Desmopressin
US Patent:
8143225, Mar 27, 2012
Filed:
Jul 15, 2008
Appl. No.:
12/173072
Inventors:
Seymour Fein - New Canaan CT, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 38/08, A61P 13/00
US Classification:
514 218, 514 157, 530330
Abstract:
The present invention is directed to a pharmaceutical composition comprising 0. 5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0. 1 picograms desmopressin per mL plasma/serum to about 10. 0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Safe Desmopressin Administration
US Patent:
2012014, Jun 14, 2012
Filed:
Jun 15, 2010
Appl. No.:
13/378778
Inventors:
Seymour Fein - New Canaan CT, US
International Classification:
A61K 38/11, A61M 31/00, A61P 7/12
US Classification:
514 109, 604151
Abstract:
Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Methods And Devices For Desmopressin Drug Delivery
US Patent:
8399410, Mar 19, 2013
Filed:
Aug 6, 2008
Appl. No.:
12/186886
Inventors:
Samuel Herschkowitz - Brooklyn NY, US
Seymour Fein - New Canaan CT, US
Seymour Fein - New Canaan CT, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K 9/22, A61K 38/08, A61M 35/00
US Classification:
514 109, 514 154, 604290, 6048901
Abstract:
Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.
Intranasal Desmopressin Administration
US Patent:
2012001, Jan 19, 2012
Filed:
Dec 21, 2009
Appl. No.:
13/141590
Inventors:
Seymour Fein - New Canaan CT, US
International Classification:
A61K 38/11, A61M 5/31, A61P 3/12
US Classification:
514 109, 604212, 604500
Abstract:
Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Pharmaceutical Compositions Including Low Dosages Of Desmopressin
US Patent:
2010005, Mar 4, 2010
Filed:
Nov 6, 2009
Appl. No.:
12/613855
Inventors:
Seymour Fein - New Canaan CT, US
International Classification:
A61K 8/64, A61P 3/10
US Classification:
514 11
Abstract:
The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Methods For Treatment Of Acute Pancreatitis
US Patent:
2005012, Jun 16, 2005
Filed:
Dec 8, 2004
Appl. No.:
11/007490
Inventors:
Seymour Fein - New Canaan CT, US
Edward Purich - Silver Spring MD, US
Edward Purich - Silver Spring MD, US
International Classification:
A61K038/54
US Classification:
424094200
Abstract:
The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.